1月17日,再鼎医药宣布KarXT(呫诺美林+曲司氯铵)用于治疗成人精神分裂症的新药上市申请(NDA)已获国家药品监督管理局(NMPA)受理。KarXT由口服M1/M4型毒蕈碱乙酰胆碱受体激动剂(即呫诺美林)和毒蕈碱受体拮抗剂(即曲司氯铵)组合而成。与目前主要针对多巴胺或血清素受体的抗精神病药物不同,呫诺美林优先刺激中枢神经系统中与这些疾病有关的毒蕈碱受体。2024年9月,KarXT获FDA批准...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.